Experimental pharmacologic approaches for the reduction of suicidal ideation and behavior

Elizabeth D. Ballard, Erica M. Richards, Dawn F. Ionescu, Mark J. Niciu, Jennifer Vande Voort, Carlos A. Zarate

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Treatment of the suicidal patient is limited by existing antidepressant medications, which can take weeks for an adequate response. New treatment approaches associated with rapid reduction of acute suicide risk are greatly needed. Experimental therapeutics-including intravenous ketamine and scopolamine-have rapid, robust, and relatively sustained reductions in suicidal thoughts within minutes to hours of administration. These findings have the potential to transform emergent treatment of the acutely suicidal patient and implicate the glutamatergic and muscarinic system in the development of suicidal thoughts and behaviors. Other putative targets for antisuicidal intervention include the thyroid and purinergic system, the latter involving the impulsive/aggressive suicide endophenotype. Benefits of research involving rapid-acting therapeutics include smaller sample sizes, short length of clinical trials, and assured compliance with study interventions. This approach also permits the evaluation of possible biomarkers of response and relapse to be incorporated into clinical trial design to more rapidly identify neurobiological correlates of suicide risk.

Original languageEnglish (US)
Title of host publicationSuicide
Subtitle of host publicationPhenomenology and Neurobiology
PublisherSpringer International Publishing
Pages209-221
Number of pages13
ISBN (Electronic)9783319099644
ISBN (Print)3319099639, 9783319099637
DOIs
StatePublished - Jul 1 2014
Externally publishedYes

Fingerprint

Suicidal Ideation
Suicide
Clinical Trials
Endophenotypes
Therapeutics
Scopolamine Hydrobromide
Ketamine
Sample Size
Cholinergic Agents
Antidepressive Agents
Thyroid Gland
Biomarkers
Recurrence
Research

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Ballard, E. D., Richards, E. M., Ionescu, D. F., Niciu, M. J., Vande Voort, J., & Zarate, C. A. (2014). Experimental pharmacologic approaches for the reduction of suicidal ideation and behavior. In Suicide: Phenomenology and Neurobiology (pp. 209-221). Springer International Publishing. https://doi.org/10.1007/978-3-319-09964-4_12

Experimental pharmacologic approaches for the reduction of suicidal ideation and behavior. / Ballard, Elizabeth D.; Richards, Erica M.; Ionescu, Dawn F.; Niciu, Mark J.; Vande Voort, Jennifer; Zarate, Carlos A.

Suicide: Phenomenology and Neurobiology. Springer International Publishing, 2014. p. 209-221.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ballard, ED, Richards, EM, Ionescu, DF, Niciu, MJ, Vande Voort, J & Zarate, CA 2014, Experimental pharmacologic approaches for the reduction of suicidal ideation and behavior. in Suicide: Phenomenology and Neurobiology. Springer International Publishing, pp. 209-221. https://doi.org/10.1007/978-3-319-09964-4_12
Ballard ED, Richards EM, Ionescu DF, Niciu MJ, Vande Voort J, Zarate CA. Experimental pharmacologic approaches for the reduction of suicidal ideation and behavior. In Suicide: Phenomenology and Neurobiology. Springer International Publishing. 2014. p. 209-221 https://doi.org/10.1007/978-3-319-09964-4_12
Ballard, Elizabeth D. ; Richards, Erica M. ; Ionescu, Dawn F. ; Niciu, Mark J. ; Vande Voort, Jennifer ; Zarate, Carlos A. / Experimental pharmacologic approaches for the reduction of suicidal ideation and behavior. Suicide: Phenomenology and Neurobiology. Springer International Publishing, 2014. pp. 209-221
@inbook{343733e4927846518d1c7c7b3b339f45,
title = "Experimental pharmacologic approaches for the reduction of suicidal ideation and behavior",
abstract = "Treatment of the suicidal patient is limited by existing antidepressant medications, which can take weeks for an adequate response. New treatment approaches associated with rapid reduction of acute suicide risk are greatly needed. Experimental therapeutics-including intravenous ketamine and scopolamine-have rapid, robust, and relatively sustained reductions in suicidal thoughts within minutes to hours of administration. These findings have the potential to transform emergent treatment of the acutely suicidal patient and implicate the glutamatergic and muscarinic system in the development of suicidal thoughts and behaviors. Other putative targets for antisuicidal intervention include the thyroid and purinergic system, the latter involving the impulsive/aggressive suicide endophenotype. Benefits of research involving rapid-acting therapeutics include smaller sample sizes, short length of clinical trials, and assured compliance with study interventions. This approach also permits the evaluation of possible biomarkers of response and relapse to be incorporated into clinical trial design to more rapidly identify neurobiological correlates of suicide risk.",
author = "Ballard, {Elizabeth D.} and Richards, {Erica M.} and Ionescu, {Dawn F.} and Niciu, {Mark J.} and {Vande Voort}, Jennifer and Zarate, {Carlos A.}",
year = "2014",
month = "7",
day = "1",
doi = "10.1007/978-3-319-09964-4_12",
language = "English (US)",
isbn = "3319099639",
pages = "209--221",
booktitle = "Suicide",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Experimental pharmacologic approaches for the reduction of suicidal ideation and behavior

AU - Ballard, Elizabeth D.

AU - Richards, Erica M.

AU - Ionescu, Dawn F.

AU - Niciu, Mark J.

AU - Vande Voort, Jennifer

AU - Zarate, Carlos A.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Treatment of the suicidal patient is limited by existing antidepressant medications, which can take weeks for an adequate response. New treatment approaches associated with rapid reduction of acute suicide risk are greatly needed. Experimental therapeutics-including intravenous ketamine and scopolamine-have rapid, robust, and relatively sustained reductions in suicidal thoughts within minutes to hours of administration. These findings have the potential to transform emergent treatment of the acutely suicidal patient and implicate the glutamatergic and muscarinic system in the development of suicidal thoughts and behaviors. Other putative targets for antisuicidal intervention include the thyroid and purinergic system, the latter involving the impulsive/aggressive suicide endophenotype. Benefits of research involving rapid-acting therapeutics include smaller sample sizes, short length of clinical trials, and assured compliance with study interventions. This approach also permits the evaluation of possible biomarkers of response and relapse to be incorporated into clinical trial design to more rapidly identify neurobiological correlates of suicide risk.

AB - Treatment of the suicidal patient is limited by existing antidepressant medications, which can take weeks for an adequate response. New treatment approaches associated with rapid reduction of acute suicide risk are greatly needed. Experimental therapeutics-including intravenous ketamine and scopolamine-have rapid, robust, and relatively sustained reductions in suicidal thoughts within minutes to hours of administration. These findings have the potential to transform emergent treatment of the acutely suicidal patient and implicate the glutamatergic and muscarinic system in the development of suicidal thoughts and behaviors. Other putative targets for antisuicidal intervention include the thyroid and purinergic system, the latter involving the impulsive/aggressive suicide endophenotype. Benefits of research involving rapid-acting therapeutics include smaller sample sizes, short length of clinical trials, and assured compliance with study interventions. This approach also permits the evaluation of possible biomarkers of response and relapse to be incorporated into clinical trial design to more rapidly identify neurobiological correlates of suicide risk.

UR - http://www.scopus.com/inward/record.url?scp=84930154900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930154900&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-09964-4_12

DO - 10.1007/978-3-319-09964-4_12

M3 - Chapter

SN - 3319099639

SN - 9783319099637

SP - 209

EP - 221

BT - Suicide

PB - Springer International Publishing

ER -